These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 18701333)

  • 1. Severity of diabetic microvascular complications is associated with a low soluble RAGE level.
    Grossin N; Wautier MP; Meas T; Guillausseau PJ; Massin P; Wautier JL
    Diabetes Metab; 2008 Sep; 34(4 Pt 1):392-5. PubMed ID: 18701333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
    Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
    Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
    Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
    Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
    Yamagishi S; Adachi H; Nakamura K; Matsui T; Jinnouchi Y; Takenaka K; Takeuchi M; Enomoto M; Furuki K; Hino A; Shigeto Y; Imaizumi T
    Metabolism; 2006 Sep; 55(9):1227-31. PubMed ID: 16919543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Diabetes Metab Res Rev; 2008 Feb; 24(2):109-14. PubMed ID: 17694504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum levels of advanced glycation end products and their monocyte receptors in patients with type 2 diabetes.
    Su XD; Li SS; Tian YQ; Zhang ZY; Zhang GZ; Wang LX
    Arch Med Res; 2011 Oct; 42(7):596-601. PubMed ID: 22100610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble receptor for advanced glycation end products in patients with decreased renal function.
    Kalousová M; Hodková M; Kazderová M; Fialová J; Tesar V; Dusilová-Sulková S; Zima T
    Am J Kidney Dis; 2006 Mar; 47(3):406-11. PubMed ID: 16490618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis.
    Basta G; Castagnini M; Del Turco S; Epistolato MC; Righini P; Sangiorgi GM; De Caterina R; Tanganelli P
    Eur J Clin Invest; 2009 Dec; 39(12):1065-72. PubMed ID: 19811526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
    Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
    Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma N-epsilon-(carboxymethyl)lysine levels are associated with the extent of vessel injury after coronary arterial stenting.
    Basta G; Berti S; Cocci F; Lazzerini G; Parri S; Papa A; Battaglia D; Lubrano V; Del Turco S; Ravani M; Rizza A; De Caterina R; Marraccini P; Mazzone A
    Coron Artery Dis; 2008 Aug; 19(5):299-305. PubMed ID: 18607166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients.
    Kalousová M; Jáchymová M; Mestek O; Hodková M; Kazderová M; Tesar V; Zima T
    Nephrol Dial Transplant; 2007 Jul; 22(7):2020-6. PubMed ID: 17347281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low levels of plasma soluble receptor for advanced glycation end products are associated with severe leukoaraiosis in acute stroke patients.
    Yokota C; Minematsu K; Tomii Y; Naganuma M; Ito A; Nagasawa H; Yamaguchi T
    J Neurol Sci; 2009 Dec; 287(1-2):41-4. PubMed ID: 19801152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts.
    Nienhuis HL; de Leeuw K; Bijzet J; Smit A; Schalkwijk CG; Graaff R; Kallenberg CG; Bijl M
    Rheumatology (Oxford); 2008 Oct; 47(10):1554-8. PubMed ID: 18701539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total plasma Nε-(carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic young-to-middle-aged medication-free subjects.
    Sebeková K; Krivošíková Z; Gajdoš M
    Clin Chem Lab Med; 2014 Jan; 52(1):139-49. PubMed ID: 23509221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage.
    Yu JY; An XF; Liu JS; Ten SC; Wang X; Zhao Y; Huang S; Gu WJ; Gao F
    Diabetes Res Clin Pract; 2010 Feb; 87(2):157-60. PubMed ID: 19945761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population.
    Norata GD; Garlaschelli K; Grigore L; Tibolla G; Raselli S; Redaelli L; Buccianti G; Catapano AL
    Nutr Metab Cardiovasc Dis; 2009 Feb; 19(2):129-34. PubMed ID: 18595673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control.
    Pullerits R; Bokarewa M; Dahlberg L; Tarkowski A
    Arthritis Res Ther; 2005; 7(4):R817-24. PubMed ID: 15987483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
    Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
    Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.
    Kaji Y; Usui T; Ishida S; Yamashiro K; Moore TC; Moore J; Yamamoto Y; Yamamoto H; Adamis AP
    Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):858-65. PubMed ID: 17251488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.